Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure
Thyroid® · 2025
DOI: 10.1089/thy.2025.0044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thyroid®, 2025. Verfasst von Maria E Cabanillas und 18 weiteren Autor:innen. Beteiligte Einrichtung: The Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Anaplastic thyroid cancer (ATC) is an aggressive cancer that leads to rapid death if left untreated. However, recent advances in ATC treatment have dramatically changed the prognosis in a select group of patients with BRAFV600E mutations. In these patients, BRAF/MEK inhibitors have been shown to dramatically and rapidly shrink tumors. Yet, these responses are short-lived unless additional treatment modalities are applied. In patients without a BRAFV600E mutation, the current available therapies are far less effective. Summary: In this article, we review the relevant literature and propose applying the "Total Therapy" approach used since the 1960s for another deadly but curable disease, acute lymphocytic leukemia, to ATC. We have adapted the concepts of Induction, Consolidation, and Maintenance, applying them to ATC. This regimen integrates the treatments we have found to be successful in ATC: combination systemic therapy using targeted therapy plus immunotherapy, surgery, radiation, and continuation of the systemic therapy for several years, thereby attempting to eradicate all residual ATC cells.
Conclusions
There has been a renewed interest in understanding the genomics of ATC and treating these patients with urgency rather than just providing palliative care. This shift has led to significant improvements in the prognosis of ATC. With the right tools and a clear roadmap to guide us, we now aim to take on the challenge of curing these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Maria E Cabanillas
Förderung
- NCI NIH HHS
Zitieren
APA
Cabanillas, M. E., Akhave, N., Banuchi, V., Busaidy, N., Dadu, R., Ferrarotto, R., Gunn, G. B., Hamidi, S., Hofmann, M. C., Hosseini, S. M., Iyer, P. C., Lai, S. Y., Lee, A., Maniakas, A., Ning, M. S., Spiotto, M., Wang, J. R., Williams, M. D., & Zafereo, M. (2025). Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure. Thyroid®. https://doi.org/10.1089/thy.2025.0044
Vancouver
Cabanillas ME, Akhave N, Banuchi V, Busaidy N, Dadu R, Ferrarotto R, et al. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure. Thyroid®. 2025. doi:10.1089/thy.2025.0044
BibTeX
@article{Cabanillas2025,
author = {Cabanillas, Maria E and Akhave, Neal and Banuchi, Victoria and Busaidy, Naifa and Dadu, Ramona and Ferrarotto, Renata and Gunn, Gary B and Hamidi, Sarah and Hofmann, Marie-Claude and Hosseini, S Mohsen and Iyer, Priyanka C and Lai, Stephen Y and Lee, Anna and Maniakas, Anastasios and Ning, Matthew S and Spiotto, Michael and Wang, Jennifer R and Williams, Michelle D and Zafereo, Mark},
title = {Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure},
journal = {Thyroid®},
year = {2025},
doi = {10.1089/thy.2025.0044}
}
EUVIMED